We also analysed the 18FLT phosphorylation k3 in the mid‐region of the lungs12 and no significant differences were observed among the PAH patients, unaffected BMPR2 mutation carriers and controls (Fig. 1c). The gene discussed is BMPR2; the disease is pulmonary arterial hypertension.